Dominic D'Agostino

It doesn't

So no, Veach told me that and I'm a believer because it gets metabolized much slower.

Yeah.

Ultimately, L-beta-hydroxybutyrate will go into acetyl-CoA, but it'll be metabolized more like a fatty acid.

The D has a redox shift and it causes a reductive shift.

Actually, you could have reductive stress.

I'm going to come to that in a minute.

But you have the D and the L, they get metabolized at different rates.

D gets metabolized slower than the L, takes about three or four times longer.

But the L seems to have- Sorry, you said D metabolized slower, I think.

Oh, I'm sorry.

D metabolized very fast and L metabolized slower.

Sorry.

But the L retains signaling effects that D does.

So for example, the NLRP3 inflammasome, so the Nature Medicine paper in 2015, doesn't seem to be enantiomer specific.

So the D will suppress it.

So that's important because if the L gets elevated in the brain, then it could inhibit

neuroinflammation and inflammatory processes.

So it's almost like the drug form of BHB.

The epigenetic effects, the signaling effects and the epigenetic effects of the L seem to be present too.